Comparative Pharmacology
Head-to-head clinical analysis: PHOSLYRA versus SEVELAMER CARBONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHOSLYRA versus SEVELAMER CARBONATE.
PHOSLYRA vs SEVELAMER CARBONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phoslyra (calcium acetate) binds dietary phosphate in the gastrointestinal tract, forming insoluble calcium phosphate complexes that are excreted in the feces, thereby reducing serum phosphate levels.
Sevelamer carbonate is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, thereby reducing phosphate absorption and serum phosphate levels. It also binds bile acids and may reduce LDL cholesterol.
1330 mg (one caplet) orally three times daily with meals, titrated to achieve serum phosphorus within target range.
Adults: 800 to 1600 mg orally three times daily with meals, titrated according to serum phosphorus targets.
None Documented
None Documented
Not applicable; Phoslyra (calcium acetate) is not absorbed systemically; local effect in GI tract.
Not applicable. Sevelamer carbonate is not systemically absorbed and thus has no measurable plasma half-life. Its pharmacological effect correlates with gastrointestinal transit time, which is typically 24-48 hours.
Renal 100% as unchanged drug, no biliary or fecal elimination.
Sevelamer carbonate is not absorbed systemically; it acts locally in the gastrointestinal tract. Excretion is entirely fecal, with no renal or biliary elimination. The polymer is excreted unchanged in the feces.
Category C
Category A/B
Phosphate Binder
Phosphate Binder